Latest News for Aclaris Therapeutics Stock (NASDAQ:ACRS)

Wednesday, December 06, 2023

Why SentinelOne Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
Lisa Levin - 40 minutes ago

Tuesday, December 05, 2023

12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights - 16 hours ago
Aclaris Therapeutics Announces Exclusive Patent License Agreement With Sun Pharma For Rights Of Deuruxolitinib; Agreement Includes Upfront Payment Of $15M Plus Milestones And Royalties
Benzinga Newsdesk - 17 hours ago

Tuesday, November 14, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Nov 14, 2023, 12:31PM
HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $9
Benzinga Newsdesk - Nov 14, 2023, 9:32AM
The Latest Analyst Ratings for Aclaris Therapeutics
Benzinga Insights - Nov 14, 2023, 8:00AM
Cantor Fitzgerald Downgrades Aclaris Therapeutics to Neutral
Benzinga Newsdesk - Nov 14, 2023, 4:10AM

Monday, November 13, 2023

Crude Oil Gains Over 1%; US Budget Deficit Narrows For October
Lisa Levin - Nov 13, 2023, 2:35PM
Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Nov 13, 2023, 1:08PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Nov 13, 2023, 12:31PM
Dow Surges 100 Points; Tenax Therapeutics Shares Spike Higher
Lisa Levin - Nov 13, 2023, 12:03PM
Stifel Downgrades Aclaris Therapeutics to Hold, Lowers Price Target to $2
Benzinga Newsdesk - Nov 13, 2023, 12:00PM
William Blair Downgrades Aclaris Therapeutics to Market Perform
Benzinga Newsdesk - Nov 13, 2023, 11:55AM
Why Is Arthritis-Focused Aclaris Therapeutics Stock Nosediving Today?
Vandana Singh - Nov 13, 2023, 9:51AM
US Stocks Fall; Tyson Foods Posts Upbeat Earnings
Lisa Levin - Nov 13, 2023, 9:47AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Nov 13, 2023, 8:06AM
Aclaris Announces Topline Results From 12-Week Phase 2b Trial Of Oral Zunsemetinib For Moderate To Severe Rheumatoid Arthritis; Study Did Not Meet Primary Or Secondary Efficacy Endpoints, Efficacy Results Do Not Support Further Development Of Zunsemetinib
Benzinga Newsdesk - Nov 13, 2023, 7:10AM

Tuesday, November 07, 2023

8 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights - Nov 7, 2023, 12:35PM

Monday, October 09, 2023

Expert Ratings for Aclaris Therapeutics
Benzinga Insights - Oct 9, 2023, 12:00PM
Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics, Maintains $38 Price Target
Benzinga Newsdesk - Oct 9, 2023, 11:53AM

Wednesday, October 04, 2023

HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $43 Price Target
Benzinga Newsdesk - Oct 4, 2023, 6:22AM

Tuesday, October 03, 2023

Benzinga's Top Ratings Upgrades, Downgrades For October 3, 2023
Benzinga Insights - Oct 3, 2023, 11:00AM
Evercore ISI Group Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $22
Benzinga Newsdesk - Oct 3, 2023, 10:20AM
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
Benzinga Newsdesk - Oct 3, 2023, 7:01AM

Tuesday, September 19, 2023

Expert Ratings for Aclaris Therapeutics
Benzinga Insights - Sep 19, 2023, 3:00PM
Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics, Maintains $38 Price Target
Benzinga Newsdesk - Sep 19, 2023, 9:10AM
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $43 Price Target
Benzinga Newsdesk - Sep 19, 2023, 6:14AM

Monday, September 18, 2023

Aclaris Therapeutics Announces Results From Phase 1 Multiple Ascending Dose Trial of ATI-2138, An Investigational Oral Covalent ITK/JAK3 Inhibitor
Benzinga Newsdesk - Sep 18, 2023, 7:05AM

Thursday, September 14, 2023

Stifel Maintains Buy on Aclaris Therapeutics, Raises Price Target to $20
Benzinga Newsdesk - Sep 14, 2023, 10:10AM

Friday, September 08, 2023

Smartsheet, Kroger, Lantronix And Other Big Stocks Moving Higher On Friday
Lisa Levin - Sep 8, 2023, 10:29AM

Tuesday, August 29, 2023

Massive Insider Trade At Aclaris Therapeutics
Benzinga Insights - Aug 29, 2023, 11:02AM
PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday
Lisa Levin - Aug 29, 2023, 10:33AM
Insiders Buying Freshpet And 2 Other Stocks
Lisa Levin - Aug 29, 2023, 7:21AM

Tuesday, August 08, 2023

HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $43 Price Target
Benzinga Newsdesk - Aug 8, 2023, 6:19AM

Monday, August 07, 2023

Aclaris Anticipates That Its Q2 Cash, Cash Equivalents And Marketable Securities As Of $210.8M Will Be Sufficient To Fund Its Operations Through The End Of 2025
Benzinga Newsdesk - Aug 7, 2023, 7:12AM
Aclaris Therapeutics Q2 EPS $(0.42) Beats $(0.45) Estimate, Sales $1.87M Miss $1.90M Estimate
Benzinga Newsdesk - Aug 7, 2023, 7:11AM

Friday, June 23, 2023

Director at Aclaris Therapeutics Exercises Options Worth $168K
Benzinga Insights - Jun 23, 2023, 11:03AM

Wednesday, June 14, 2023

HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $43 Price Target
Benzinga Newsdesk - Jun 14, 2023, 6:17AM

Tuesday, June 13, 2023

Aclaris Therapeutics Completes Enrollment In Phase 2B Study Of Oral Zunsemetinib (ATI-450) For Moderate To Severe Rheumatoid Arthritis; Topline Data Anticipated In Q4 2023
Benzinga Newsdesk - Jun 13, 2023, 7:07AM

Monday, May 22, 2023

Aclaris Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Insights - May 22, 2023, 10:48AM

Monday, May 08, 2023

Earnings Scheduled For May 8, 2023
Benzinga Insights - May 8, 2023, 9:03AM
Aclaris Therapeutics Q1 EPS $(0.42) Beats $(0.44) Estimate, Sales $2.53M Beat $1.75M Estimate
Benzinga Newsdesk - May 8, 2023, 7:02AM

Friday, May 05, 2023

Aclaris Therapeutics's Earnings Outlook
Benzinga Insights - May 5, 2023, 11:03AM

Thursday, April 27, 2023

Foghorn Therapeutics Soars 13.1%: Is Further Upside Left In the Stock?
Zacks - Apr 27, 2023, 8:42AM

Wednesday, March 08, 2023

(ACRS) - Analyzing Aclaris Therapeutics's Short Interest
Benzinga Insights - Mar 8, 2023, 1:31PM

Tuesday, March 07, 2023

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Vandana Singh - Mar 7, 2023, 7:34PM
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Mar 7, 2023, 1:02PM
Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday
Lisa Levin - Mar 7, 2023, 10:31AM
DocuSign To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday
Lisa Levin - Mar 7, 2023, 7:39AM
Goldman Sachs Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $21
Benzinga Newsdesk - Mar 7, 2023, 7:33AM

Open-	Close-
Vol / Avg.1.546M / 3.959M	Mkt Cap74.378M
Day Range- - -	52 Wk Range0.590 - 18.540

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Aclaris Therapeutics Stock (NASDAQ:ACRS)

Wednesday, December 06, 2023

Tuesday, December 05, 2023

Tuesday, November 14, 2023

Monday, November 13, 2023

Tuesday, November 07, 2023

Monday, October 09, 2023

Wednesday, October 04, 2023

Tuesday, October 03, 2023

Tuesday, September 19, 2023

Monday, September 18, 2023

Thursday, September 14, 2023

Friday, September 08, 2023

Tuesday, August 29, 2023

Tuesday, August 08, 2023

Monday, August 07, 2023

Friday, June 23, 2023

Wednesday, June 14, 2023

Tuesday, June 13, 2023

Monday, May 22, 2023

Monday, May 08, 2023

Friday, May 05, 2023

Thursday, April 27, 2023

Wednesday, March 08, 2023

Tuesday, March 07, 2023